We correlated the expression of IGF2BP3 with the patient outcome in a high-risk pediatric B-ALL cohort, in which a higher-than-median IGF2BP3 mRNA level was associated with improved survival. This evidence concerns the gene IGF2BP3 and acute lymphoblastic leukemia.